Trials / Terminated
TerminatedNCT02288208
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- TetraLogic Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will receive either birinapant or placebo in addition to their anti-viral therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antiviral Therapy (tenofovir or entecavir) | |
| DRUG | Birinapant | |
| DRUG | Placebo (for birinapant) |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-11-11
- Last updated
- 2016-02-05
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02288208. Inclusion in this directory is not an endorsement.